Lista de obras -

A CTC-Cluster-Specific Signature Derived from OMICS Analysis of Patient-Derived Xenograft Tumors Predicts Outcomes in Basal-Like Breast Cancer

artículo científico publicado en 2019

A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer

artículo científico publicado en 2022

A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models

artículo científico publicado en 2013

Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators

artículo científico publicado en 2005

Advances in breast cancer treatment and prevention: preclinical studies on aromatase inhibitors and new selective estrogen receptor modulators (SERMs)

artículo científico publicado en 2003

Amplification and over-expression of MAP3K3 gene in human breast cancer promotes formation and survival of breast cancer cells.

artículo científico publicado en 2014

Amplification of TLK2 Induces Genomic Instability via Impairing the G2-M Checkpoint.

artículo científico publicado en 2016

Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications

scientific article published on August 2013

Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer

artículo científico publicado en 2013

Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy

artículo científico publicado en 2005

Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance.

artículo científico publicado en 2016

Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response.

artículo científico publicado en 2003

Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysis

artículo científico publicado en 2019

Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer.

artículo científico publicado en 2018

Compartmentalized Ras Proteins Transform NIH 3T3 Cells with Different Efficiencies ⬇️

artículo científico publicado el 28 de diciembre de 2010

Comprehensive functional analysis of the tousled-like kinase 2 frequently amplified in aggressive luminal breast cancers

artículo científico publicado en 2016

Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance

artículo científico publicado en 2004

Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer

artículo científico publicado en 2005

Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance

artículo científico publicado en 2008

Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer

Cytoplasmic estrogen receptor in breast cancer

artículo científico publicado en 2011

De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance

artículo científico publicado en 2017

Development of Acneiform Rash Does Not Predict Response to Lapatinib Treatment in Patients with Breast Cancer ⬇️

artículo científico publicado el 6 de junio de 2013

Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts

artículo científico publicado en 2008

Die and let live: harnessing BikDD to combat breast cancer stem cells ⬇️

artículo científico publicado el 23 de mayo de 2012

Different mechanisms for resistance to trastuzumab versus lapatinib in HER2- positive breast cancers - role of estrogen receptor and HER2 reactivation ⬇️

artículo científico publicado el 28 de noviembre de 2011

ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer

artículo científico publicado en 2015

Embryonic transcription factor SOX9 drives breast cancer endocrine resistance

artículo científico publicado en 2017

Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy

artículo científico publicado en 2005

Endocrinology and hormone therapy in breast cancer: new insight into estrogen receptor-alpha function and its implication for endocrine therapy resistance in breast cancer

artículo científico publicado en 2005

Enhancer reprogramming driven by high-order assemblies of transcription factors promotes phenotypic plasticity and breast cancer endocrine resistance

artículo científico publicado en 2020

Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes

artículo científico publicado en 2010

Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer

artículo científico publicado en 2014

Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters ⬇️

artículo científico publicado el 15 de mayo de 2003

Estrogen receptor positivity in mammary tumors of Wnt-1 transgenic mice is influenced by collaborating oncogenic mutations

artículo científico publicado en 2005

Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance

artículo científico publicado en 2005

Estrogen-induced transcription at individual alleles is independent of receptor level and active conformation but can be modulated by coactivators activity

artículo científico publicado en 2020

Estrogen-mediated down-regulation of E-cadherin in breast cancer cells ⬇️

artículo científico publicado el 1 de septiembre de 2003

Estrogen-receptor biology: continuing progress and therapeutic implications

artículo científico publicado en 2005

Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy

scientific article published on 25 October 2019

FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer

artículo científico publicado en 2016

FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer

scientific article published on 11 December 2019

GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer

artículo científico publicado en 2018

Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor–Positive Metastatic Breast Cancer: A Randomized Phase II Study ⬇️

artículo científico publicado el 10 de enero de 2011

Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer

artículo científico publicado en 2003

HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer

artículo científico publicado en 2017

HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade

artículo científico publicado en 2020

HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis

artículo científico publicado en 2020

Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer

artículo científico publicado en 2009

In vivo longitudinal imaging of RNA interference-induced endocrine therapy resistance in breast cancer

scientific article published on 09 October 2019

Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibition

scientific article published on 17 June 2020

Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth

artículo científico publicado en 2002

Loss of Phosphatase and Tensin Homolog or Phosphoinositol-3 Kinase Activation and Response to Trastuzumab or Lapatinib in Human Epidermal Growth Factor Receptor 2–Overexpressing Locally Advanced Breast Cancers ⬇️

artículo científico publicado el 6 de diciembre de 2010

Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer

artículo científico publicado en 2017

Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer

artículo científico publicado en 2004

Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer

artículo científico publicado en 2006

Microscaled proteogenomic methods for precision oncology

scientific article published on 27 January 2020

Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase

artículo científico publicado en 2005

Molecular profiles of progesterone receptor loss in human breast tumors

artículo científico publicado en 2008

More on FOX News: FOXA1 on the horizon of estrogen receptor function and endocrine response ⬇️

artículo científico publicado el 20 de abril de 2011

Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: TBCRC 006 ⬇️

artículo científico publicado el 8 de abril de 2013

Neoadjuvant trastuzumab induces apoptosis in primary breast cancers

artículo científico publicado en 2005

New mechanisms of signal transduction inhibitor action: receptor tyrosine kinase down-regulation and blockade of signal transactivation.

artículo científico publicado en 2003

PDEF promotes luminal differentiation and acts as a survival factor for ER-positive breast cancer cells

artículo científico publicado en 2013

PTK6 regulates growth and survival of endocrine therapy-resistant ER+ breast cancer cells

artículo científico publicado en 2017

Perspective on Circulating Tumor Cell Clusters: Why It Takes a Village to Metastasize

artículo científico publicado en 2018

Proceedings of the Third International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: Conference Summary Statement

artículo científico publicado en 2004

Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer

artículo científico publicado en 2010

Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers

artículo científico publicado en 2014

Reduced Dose and Intermittent Treatment with Lapatinib and Trastuzumab for Potent Blockade of the HER Pathway in HER2/neu-Overexpressing Breast Tumor Xenografts ⬇️

artículo científico publicado el 7 de diciembre de 2010

Resistance to Anti-HER2 Therapies in Breast Cancer.

artículo científico

Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk

artículo científico publicado en 2006

Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer

artículo científico publicado en 2003

SGK3 is associated with estrogen receptor expression in breast cancer ⬇️

artículo científico publicado el 11 de mayo de 2012

Somatic Expression of PyMT or Activated ErbB2 Induces Estrogen-Independent Mammary Tumorigenesis ⬇️

artículo científico publicado el 1 de septiembre de 2010

Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical Outcomes

artículo científico publicado en 2016

TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer

scientific article published on 29 October 2019

Tamoxifen resistance in breast cancer is regulated by the EZH2-ERα-GREB1 transcriptional axis.

artículo científico publicado en 2017

Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function

artículo científico publicado en 2008

Targeting HER2 for the treatment of breast cancer

artículo científico publicado en 2015

Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast Cancer

scientific article published on 16 August 2019

The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast Cancer

artículo científico publicado en 2017

The changing role of ER in endocrine resistance

artículo científico publicado en 2015

The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth

artículo científico publicado en 2006

The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance

artículo científico publicado en 2018

The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo ⬇️

artículo científico publicado el 9 de febrero de 2011

Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance

artículo científico publicado en 2014

Towards personalized treatment for early stage HER2-positive breast cancer

artículo científico publicado en 2019

Tracking of multimodal therapeutic nanocomplexes targeting breast cancer in vivo.

artículo científico publicado en 2010

Trastuzumab-Resistant HER2+ Breast Cancer Cells Retain Sensitivity to Poly (ADP-Ribose) Polymerase (PARP) Inhibition

artículo científico publicado en 2018

Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy

artículo científico publicado en 2007

Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities

artículo científico publicado en 2007

Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies ⬇️

artículo científico publicado el 29 de mayo de 2012

β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib ⬇️

artículo científico publicado el 31 de agosto de 2011

Lista de obras de

A CTC-Cluster-Specific Signature Derived from OMICS Analysis of Patient-Derived Xenograft Tumors Predicts Outcomes in Basal-Like Breast Cancer

A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer

A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models

Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators

Advances in breast cancer treatment and prevention: preclinical studies on aromatase inhibitors and new selective estrogen receptor modulators (SERMs)

Amplification and over-expression of MAP3K3 gene in human breast cancer promotes formation and survival of breast cancer cells.

Amplification of TLK2 Induces Genomic Instability via Impairing the G2-M Checkpoint.

Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications

Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer

Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy

Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance.

Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response.

Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysis

Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer.

Compartmentalized Ras Proteins Transform NIH 3T3 Cells with Different Efficiencies ⬇️

Comprehensive functional analysis of the tousled-like kinase 2 frequently amplified in aggressive luminal breast cancers

Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance

Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer

Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance

Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer

Cytoplasmic estrogen receptor in breast cancer

De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance

Development of Acneiform Rash Does Not Predict Response to Lapatinib Treatment in Patients with Breast Cancer ⬇️

Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts

Die and let live: harnessing BikDD to combat breast cancer stem cells ⬇️

Different mechanisms for resistance to trastuzumab versus lapatinib in HER2- positive breast cancers - role of estrogen receptor and HER2 reactivation ⬇️

ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer

Embryonic transcription factor SOX9 drives breast cancer endocrine resistance

Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy

Endocrinology and hormone therapy in breast cancer: new insight into estrogen receptor-alpha function and its implication for endocrine therapy resistance in breast cancer

Enhancer reprogramming driven by high-order assemblies of transcription factors promotes phenotypic plasticity and breast cancer endocrine resistance

Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes

Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer

Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters ⬇️

Estrogen receptor positivity in mammary tumors of Wnt-1 transgenic mice is influenced by collaborating oncogenic mutations

Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance

Estrogen-induced transcription at individual alleles is independent of receptor level and active conformation but can be modulated by coactivators activity

Estrogen-mediated down-regulation of E-cadherin in breast cancer cells ⬇️

Estrogen-receptor biology: continuing progress and therapeutic implications

Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy

FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer

FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer

GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer

Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor–Positive Metastatic Breast Cancer: A Randomized Phase II Study ⬇️

Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer

HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer

HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade

HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis

Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer

In vivo longitudinal imaging of RNA interference-induced endocrine therapy resistance in breast cancer

Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibition

Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth

Loss of Phosphatase and Tensin Homolog or Phosphoinositol-3 Kinase Activation and Response to Trastuzumab or Lapatinib in Human Epidermal Growth Factor Receptor 2–Overexpressing Locally Advanced Breast Cancers ⬇️

Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer

Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer

Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer

Microscaled proteogenomic methods for precision oncology

Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase

Molecular profiles of progesterone receptor loss in human breast tumors

More on FOX News: FOXA1 on the horizon of estrogen receptor function and endocrine response ⬇️

Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: TBCRC 006 ⬇️

Neoadjuvant trastuzumab induces apoptosis in primary breast cancers

New mechanisms of signal transduction inhibitor action: receptor tyrosine kinase down-regulation and blockade of signal transactivation.

PDEF promotes luminal differentiation and acts as a survival factor for ER-positive breast cancer cells

PTK6 regulates growth and survival of endocrine therapy-resistant ER+ breast cancer cells

Perspective on Circulating Tumor Cell Clusters: Why It Takes a Village to Metastasize

Proceedings of the Third International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: Conference Summary Statement

Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer

Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers

Reduced Dose and Intermittent Treatment with Lapatinib and Trastuzumab for Potent Blockade of the HER Pathway in HER2/neu-Overexpressing Breast Tumor Xenografts ⬇️

Resistance to Anti-HER2 Therapies in Breast Cancer.

Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk

Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer

SGK3 is associated with estrogen receptor expression in breast cancer ⬇️

Somatic Expression of PyMT or Activated ErbB2 Induces Estrogen-Independent Mammary Tumorigenesis ⬇️

Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical Outcomes

TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer

Tamoxifen resistance in breast cancer is regulated by the EZH2-ERα-GREB1 transcriptional axis.

Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function